MedTrace Logo

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

NCT05481463 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-05-28

No results posted yet for this study

Summary

This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with TAS-102 in third-line and later-line therapy of patients with advanced pancreatic cancer

Conditions

  • Pancreatic Neoplasms

Interventions

DRUG

Surufatinib

surufatinib,250mg, qd, po, 28 days for a cycle

DRUG

TAS-102

TAS-102,35mg/m2, po, d1-5, d8-12, bid, 28 days for a cycle

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Dongsheng Zhang, PhD · Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-30
Primary Completion
2025-03-31
Completion
2025-05-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05481463 on ClinicalTrials.gov